Argosy Research Inc. (TPEX:3217)
Taiwan · Delayed Price · Currency is TWD 184.50
+15.50 (9.17%)
Aug 12, 2025, 1:30 PM CST
Silk Road Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 3,976 | 3,473 | 3,004 | 2,608 | 3,016 | 2,598 | Upgrade | |
Revenue Growth (YoY) | 25.41% | 15.64% | 15.15% | -13.53% | 16.09% | 18.51% | Upgrade |
Cost of Revenue | 1,976 | 1,736 | 1,602 | 1,583 | 1,746 | 1,350 | Upgrade |
Gross Profit | 2,000 | 1,738 | 1,401 | 1,025 | 1,270 | 1,248 | Upgrade |
Selling, General & Admin | 477.92 | 449.99 | 379.89 | 301.26 | 308.93 | 312.85 | Upgrade |
Research & Development | 237.45 | 226.41 | 194.75 | 183.96 | 176.48 | 155.26 | Upgrade |
Operating Expenses | 715.37 | 680.9 | 574.58 | 485.28 | 485.33 | 468.19 | Upgrade |
Operating Income | 1,285 | 1,057 | 826.85 | 539.68 | 785.03 | 779.94 | Upgrade |
Interest Expense | -0.25 | -0.25 | -0.68 | -0.31 | -0.2 | -0.45 | Upgrade |
Interest & Investment Income | 74.11 | 74.75 | 54 | 49.34 | 31.99 | 25.22 | Upgrade |
Currency Exchange Gain (Loss) | 84.17 | 84.17 | 2.02 | 147.65 | -22.87 | -57.19 | Upgrade |
Other Non Operating Income (Expenses) | -133.87 | 15.24 | 41.95 | 24.17 | 19.75 | 11.66 | Upgrade |
EBT Excluding Unusual Items | 1,309 | 1,231 | 924.14 | 760.53 | 813.7 | 759.19 | Upgrade |
Impairment of Goodwill | - | - | - | - | -10.23 | - | Upgrade |
Gain (Loss) on Sale of Assets | 34.58 | 34.58 | -0.01 | 0.1 | 2.36 | 0.44 | Upgrade |
Pretax Income | 1,344 | 1,265 | 924.13 | 760.63 | 805.83 | 759.63 | Upgrade |
Income Tax Expense | 278.59 | 252.04 | 195.46 | 149.96 | 166.78 | 147.92 | Upgrade |
Earnings From Continuing Operations | 1,065 | 1,013 | 728.68 | 610.67 | 639.06 | 611.71 | Upgrade |
Minority Interest in Earnings | - | - | - | - | 1.17 | - | Upgrade |
Net Income | 1,065 | 1,013 | 728.68 | 610.67 | 640.22 | 611.71 | Upgrade |
Net Income to Common | 1,065 | 1,013 | 728.68 | 610.67 | 640.22 | 611.71 | Upgrade |
Net Income Growth | 18.61% | 39.07% | 19.32% | -4.62% | 4.66% | 39.46% | Upgrade |
Shares Outstanding (Basic) | 90 | 90 | 90 | 90 | 90 | 85 | Upgrade |
Shares Outstanding (Diluted) | 90 | 90 | 90 | 90 | 90 | 85 | Upgrade |
Shares Change (YoY) | 0.05% | 0.23% | 0.15% | -0.38% | 6.10% | 3.43% | Upgrade |
EPS (Basic) | 11.82 | 11.25 | 8.11 | 6.80 | 7.11 | 7.20 | Upgrade |
EPS (Diluted) | 11.82 | 11.25 | 8.11 | 6.80 | 7.11 | 7.20 | Upgrade |
EPS Growth | 18.55% | 38.75% | 19.14% | -4.25% | -1.36% | 34.83% | Upgrade |
Free Cash Flow | 940.61 | 899.26 | 544.2 | 730.19 | 270.01 | 568.87 | Upgrade |
Free Cash Flow Per Share | 10.43 | 9.98 | 6.05 | 8.13 | 3.00 | 6.70 | Upgrade |
Dividend Per Share | - | - | 6.400 | 5.350 | 5.600 | 5.600 | Upgrade |
Dividend Growth | - | - | 19.63% | -4.46% | - | 30.23% | Upgrade |
Gross Margin | 50.31% | 50.03% | 46.66% | 39.30% | 42.11% | 48.03% | Upgrade |
Operating Margin | 32.32% | 30.43% | 27.53% | 20.69% | 26.02% | 30.02% | Upgrade |
Profit Margin | 26.79% | 29.18% | 24.26% | 23.41% | 21.22% | 23.54% | Upgrade |
Free Cash Flow Margin | 23.66% | 25.89% | 18.12% | 27.99% | 8.95% | 21.89% | Upgrade |
EBITDA | 1,410 | 1,188 | 951.6 | 660.9 | 894.55 | 874.9 | Upgrade |
EBITDA Margin | 35.47% | 34.19% | 31.68% | 25.34% | 29.66% | 33.67% | Upgrade |
D&A For EBITDA | 125.14 | 130.63 | 124.75 | 121.22 | 109.53 | 94.95 | Upgrade |
EBIT | 1,285 | 1,057 | 826.85 | 539.68 | 785.03 | 779.94 | Upgrade |
EBIT Margin | 32.32% | 30.43% | 27.53% | 20.69% | 26.02% | 30.02% | Upgrade |
Effective Tax Rate | 20.73% | 19.92% | 21.15% | 19.71% | 20.70% | 19.47% | Upgrade |
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.